Previous 10 | Next 10 |
The World Health Organization (WHO) said that individuals should wear masks in certain situations irrespective of the local spread of COVID-19 given the current spread of the virus worldwide. Masks are recommended if one has had recent exposure to COVID, when someone has or suspects they have...
Summary CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't produce double-strand breaks in DNA. During the market turmoil of late last...
Summary Alnylam's fourth quarter product revenue was more or less as expected, with a faster/better-than-expected pace of switching between Onpattro and Amvuttra and further patient growth in Oxlumo and Givlaari. Investors will have multiple clinical read-outs to anticipate this year, i...
Summary I significantly pruned my watchlist, removing a number of companies and adding in some high quality companies. I discuss my strategy of focusing on high quality companies and the mistakes I made including some cheap companies on previous watchlists. I name the top companies ...
Regeneron Pharmaceuticals, Inc. (REGN) 41st Annual J.P. Morgan Healthcare Conference January 09, 2023, 12:00 PM ET Company Participants Leonard Schleifer - President and CEO George Yancopoulos - President and Chief Scientific Officer Marion McCourt - EVP and Head of Co...
Regeneron ( NASDAQ: REGN ) shares lost ~5% to reach the lowest level in more than three months on Monday after the drugmaker announced a $0.21 impact to GAAP and non-GAAP net income per diluted share in Q4 2022 due to a one-off R&D charge. Issuing a regulatory filing ahead of ...
Summary ARK Invest's Cathie Wood believes Exact Sciences (EXAS) can hit $140 per share by 2027. Unlike some other calls, I believe Cathie and ARK are spot-on with EXAS. EXAS is a major holding in both Cathie's ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG). Together, it...
In the middle of December, Sanofi 's (NASDAQ: SNY) and Regeneron Pharmaceuticals ' (NASDAQ: REGN) immunology drug Dupixent received more positive regulatory news. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended the drug's approval ...
TARRYTOWN, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Friday, February 3, 2023, before the U.S. financial markets open. The Company will ho...
Summary Harris Associates’ 13F portfolio value decreased from $62.85B to $59.68B this quarter. They added Warner Bros. Discovery and increased Salesforce, KKR, and Oracle while decreasing Keurig Dr Pepper and Humana. The top three positions are Alphabet, Fiserv, and Amazon.co...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...